海利生物(603718.SH):2021年度淨利預增493.73%-605.75%
格隆匯1月28日丨海利生物(603718.SH)披露2021年度業績預增公吿,預計2021年度實現歸屬於上市公司股東的淨利潤將在5300萬元到6300萬元之間,同比增長493.73%到605.75%;預計歸屬於上市公司股東的扣除非經常性損益的淨利潤將在2100萬元到2900萬元之間,同比增長240.80%到294.43%。
2020年由於受新冠肺炎疫情、非洲豬瘟疫情的雙重影響以及子公司停產的影響,公司總體業務下滑,整體業績處於較低水平,但疫情對公司業務的長期發展不會造成重大影響。非洲豬瘟疫情使養殖户主動提高了對防疫的重視程度,帶動了整體對疫苗使用的需求,因此2021年隨着相關疫情的緩解,公司各項業務逐步恢復。
2021年營業收入相比去年同期增長約34%,尤其是因停產改造虧損嚴重的控股子公司楊凌金海生物技術有限公司在恢復生產後,2021年銷售迅速恢復,收入增長超過170%,虧損額大幅減少,使得公司總體業績實現了較大幅度的增長,公司主營業務呈現出健康發展的勢頭。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.